The symposium “New criteria of resectability for pancreatic cancer” was held during the 33nd meeting of the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS) in 2021 to discuss the potential modifications that could be made in the current resectability classification. The meeting focused on setting the foundation for developing a new prognosis-based resectability classification that is based on the tumor biology and the response to neoadjuvant treatment (NAT). The symposium included selected experts from Western and Eastern high-volume centers who have discussed their concept of resectability status through published literature. During the symposium, presenters reported new resectability classifications from their respective institutions based on tumor biology, conditional status, pathology, and genetics, in addition to anatomical tumor involvement. Interestingly, experts from all the centers reached the agreement that anatomy alone is insufficient to define resectability in the current era of effective NAT. On behalf of the JSHBPS, we would like to summarize the content of the conference in this position paper. We also invite global experts as internal reviewers of this paper for intercontinental cooperation in creating an up-to-date, prognosis-based resectability classification that reflects the trends of contemporary clinical practice.

中文翻译：

---

胰腺癌可切除性的新标准：日本肝胆胰外科学会 (JSHBPS) 的立场文件

在 2021 年日本肝胆胰外科学会 (JSHBPS) 第 33 次会议期间举行了题为“胰腺癌可切除性新标准”的座谈会，讨论可对当前可切除性分类进行的潜在修改。会议的重点是为开发一种新的基于预后的可切除性分类奠定基础，该分类基于肿瘤生物学和对新辅助治疗 (NAT) 的反应。研讨会包括来自西方和东方高容量中心的选定专家，他们通过已发表的文献讨论了他们对可切除性状态的概念。在研讨会期间，主持人报告了各自机构根据肿瘤生物学、条件状态、病理学和遗传学对可切除性进行的新分类，除了解剖肿瘤受累。有趣的是，来自所有中心的专家一致认为，在当前有效 NAT 时代，仅解剖学不足以定义可切除性。我们谨代表 JSHBPS 在这份立场文件中总结会议的内容。我们还邀请全球专家作为本文的内部审稿人，以进行洲际合作，以创建反映当代临床实践趋势的最新的、基于预后的可切除性分类。